Regaal Resources standalone Q1 FY27: revenue down 18% YoY on capacity ramp-up, PAT up 47%
PAT +47% YoY · revenue -18.02% · margins expanding
₹202.15 Cr
-18.02% YoY
₹13.33 Cr
+47% YoY
6.58%
+2.9pp YoY
₹1.3
Regaal Resources' standalone Q1 FY27 (quarter ended June 30, 2026) revenue fell 18.0% YoY to ₹202.15 Cr (₹246.57 Cr in Q1 FY26) and 17.4% sequentially from ₹244.61 Cr in Q4 FY26. PAT nonetheless rose 47.0% YoY to ₹13.33 Cr (₹9.07 Cr a year ago), though it slipped 19.4% QoQ from ₹16.54 Cr. Basic EPS was ₹1.30 versus ₹1.10 YoY and ₹1.63 QoQ. No consensus estimates for the quarter turned up in a search (this is a small-cap, ~₹847 Cr market cap per a Univest preview), so vsStreet is unknown; management itself has issued no formal FY27 guidance, having explicitly deferred it until a quarter of stabilized post-expansion operations, expected by end of H1 FY27 — so this print has no numeric bar to be graded against, only that qualitative marker.
Q1 FY-2027 vs prior quarters
On margins, OPM (EBITDA/revenue, adding back finance cost and depreciation, excluding other income) expanded to roughly 15.3% from 9.9% a year ago, and NPM to 6.6% from 3.7%, even with revenue down — the gain traces to lower raw-material intensity (cost of materials plus stock-in-trade purchases fell to about 66% of revenue from 72% YoY), partly offset by higher other expenses (₹41.53 Cr vs ₹30.00 Cr YoY) tied to the capacity build-out. Sequentially, though, NPM eased slightly from 6.75% in Q4 FY26 as PAT fell faster than revenue. Since neither this quarter nor the year-ago quarter carries an exceptional item, the 47% YoY PAT growth is on a clean, comparable base.
What the summary numbers don't show
No exceptional items this quarter (unlike FY26's full year, which carried a ₹6.66 Cr SGST-subsidy exceptional provision); YoY PAT growth is on a clean base both periods.
Management is refraining from providing formal earnings guidance for FY27 until a quarter of stabilized operations post-expansion commissioning, expected by the end of H1 FY27. They anticipate significant revenue growth, potentially doubling existing levels, driven by the new 1,650 TPD capacity and a substantial increa
— This quarter: missed
The revenue dip lines up with note 6 in the filing: during the quarter the company commissioned its expanded maize-crushing capacity from 825 TPD to 1,650 TPD, plus new 180 TPD Liquid Glucose and 50 TPD Maltodextrin Powder facilities, and lifted captive co-generation power from 7.1 MW to 15.8 MW — commissioning disruption during ramp-up is the likely driver of softer volumes even as the company enters an expanded capacity base. Against May 2026 concall commentary anticipating "significant revenue growth, potentially doubling" FY27 revenue and a value-added product mix rising from 2-3% to 20-25%, this quarter shows no sign of that inflection yet — expected given the mid-quarter commissioning timeline, but it leaves the FY27 growth story unproven one quarter in. Post quarter-end, the company allotted 2.70 lakh ESOP shares on July 21, 2026, lifting paid-up capital to ₹51.50 Cr from ₹51.36 Cr. No press release or management commentary beyond the regulatory filing was available to corroborate this framing further.
W1
Whether Q2 FY27 shows the revenue ramp management anticipated now that 1,650 TPD crushing, LG and MDP lines are commissioned — management flagged stabilization 'by end of H1 FY27.'
W2
Value-added product mix, guided to rise from 2-3% in FY26 to 20-25% in FY27, as new LG/MDP capacity ramps.
W3
Margin trajectory (OPM ~15.3% this quarter) as the ₹140 Cr further VAP/co-gen capex plays out and utilization improves.
Standalone-only filing (no consolidated statement present). Figures reported in Rs. Millions, converted to Cr by dividing by 10. No exceptional item this quarter or in year-ago quarter (FY26 full-year exceptional item of Rs.66.57mn / Rs.6.66 Cr, an SGST-subsidy provision, sits only in the annual column). EPS is basic, not annualised, per filing convention.
Capacity Doubled, Revenue Fell 18%: Regaal's Margin Win Hinges on Ramp-Up
Q1 revenue collapsed 18% YoY despite 1,650 TPD capacity coming online, but net profit jumped 47% on aggressive mix shift to value-added products. The transition is real—but the company must prove it can ramp utilization to 80%+ and deliver on new-product commercialization.
₹13.3 Cr
+47% YoY
₹31.0 Cr
+26.6% YoY, 15.3% margin
₹80.5 Cr
+30.3% YoY, 39.8% margin
₹202.1 Cr
-18% YoY (trading -19.5%→-3.3%)
69.7k MT
+5.5k from new capacity
71.4%
9-day integration loss ~7.2k MT
On the surface: revenue down 18%, profit up 47%. On the call, management frames Q1 as a 'transition quarter'—9 days of planned integration shutdowns at the new facility, plus new products still ramping. That framing is credible. But there's a critical question underneath: Can the company execute the utilization ramp and new-product commercialization fast enough to validate the long-term thesis? The street is pricing in execution—FII and DII are trimming—and the stock sits near its all-time high. Miss, and it's vulnerable.
Where the profit really came from
The ₹13.3 Cr PAT looks strong in isolation (+47% YoY). Break it down: Q1 EBITDA hit ₹31.0 Cr (+26.6% YoY), a real increase driven by three factors. First, deliberate reduction in low-margin trading—trading fell from 19.5% of prior-year revenue to 3.3% this quarter, shifting the revenue mix away from commodities toward higher-margin manufacturing. Second, value-added products grew 30.3% YoY to ₹80.5 Cr and hit a 39.8% margin—far higher than commodity starch. Third, operating leverage kicked in as the new 1,650 TPD capacity (doubled from 825) absorbed fixed costs across a growing revenue base. The net margin expanded 291 basis points (5.75%→6.6% NPM). This is not a one-time boost; it's a strategic mix shift—the kind management is betting on for FY28.
Value-added products grew 30.3% YoY to ₹80.53 Cr with 39.8% margin
₹80.53 Cr value-added, +30.3% YoY, 1,477 bps margin expansion to 39.8%
Supported
Revenue decline 18% YoY due to deliberate reduction in trading
₹202.1 Cr (vs. ~₹246.5 Cr prior year); trading 19.5%→3.3%
Supported
EBITDA rose 26.6% YoY to ₹30.98 Cr with 15.3% margin
₹30.98 Cr EBITDA, 15.3% OPM (+540 bps YoY)
Supported
Crushing volumes +5.5k MT; integration loss quantified at ~7.2k MT
69.7k MT Q1 (+8% YoY); 9-day shutdown × ~800 TPD
Supported (integration loss credible for new facility)
FY27 crushing volumes expected 400k+ tons vs. 265k FY26
Quantified forward guidance; ~50% growth, not prior 'potentially doubling'
Downgraded (realistic for transition year, but miss vs. prior rhetoric)
What changed on this call
Management walked back the aspirational rhetoric. Prior guidance (FY-26 calls) spoke of 'potentially doubling revenue' and '20–25% value-added by FY27.' Q1 reality: revenue down 18% (transition conceit credible, but still a miss), and FY27 guidance is now 400k+ tons (~50% growth vs. FY26's 265k)—not doubling. For value-added, the FY27 target is now 20–22% of total revenue (lower bound of prior range), with FY28 targeted at 30–35%. This is a downgrade, not a cut, but it signals management is being realistic about ramp-up speed.
On commodities, management explicitly refused to guide EBITDA per ton, citing uncontrollable maize and finished-goods price exposure. Maize is currently ₹22.5–24/kg (vs. ₹26–27 peak last year); starch prices move 1:1 with maize in a pass-through model. This means EBITDA per ton stays flat even if total EBITDA grows (due to volume/mix). The company is holding 80% of its FY27 raw material purchases (maize) in inventory, hedging near-term price spikes, but it's also inflating the working capital cycle (208 days inventory, ₹735 Cr peak debt in H1).
On capex, management deferred future expansion. Zero capex planned for FY27; the focus is on stabilizing the ₹664 Cr project (₹552 Cr already spent by Jun 30) and deleveraging. Next expansion is post-FY27, pending utilization ramp and debt reduction.
Value-added margin 39.8% Q1; designed 50:50 capacity split supports 30–35% revenue mix at full utilization
Track record: 825 TPD liquid glucose expanded prior, sold out completely
Export penetration doubled 5%→10% in single quarter; opening South/West markets for value-added
Bihar maize quality superior (280–290g per 100 grains); direct farmer procurement lowers costs
Interest cost hedged via Bihar subvention; FY27 interest flat ₹39–40 Cr despite raised debt
Revenue down 18% YoY despite capacity doubling—headline miss on growth narrative
Utilization only 71% post-commissioning; ramp to 80%+ is critical to the bull case
New products (maltodextrin, dextrose, modified starch) ramping through Q4; pricing power unproven
Peak debt ₹735 Cr; deleveraging depends on flawless execution
Commodity exposure unquantified; EBITDA per ton flat if maize/starch prices move together
Competition from Ambuja and Sanstar on specialty starch; value-added pricing power untested
Working capital cycle 130 days, inventory 208 days; cash generation delayed
Utilization ramp-up stalls at 75–78%
HighQ1 at 71.4% post-commissioning. If Q2–Q3 utilization doesn't hit 80%+, volume targets (400k+ tons FY27, 100–110k Q2) miss. Operating leverage disappears, margin expansion story stalls.
New product commercialization fails (maltodextrin, modified starch, dextrose)
HighLiquid glucose 70% live; dextrose Q4. Customer acceptance and pricing on specialty segments unproven. If new products don't hit pricing targets, value-added margin target (20–22% FY27) misses.
Commodity price exposure—maize/starch correlation
HighEBITDA per ton is 'whole-number trade'—if maize +₹1/kg, starch +₹1/kg (offsetting). Margin expansion depends on volume/mix, not price leverage. Sep maize spike risk is real.
Peak debt ₹735 Cr; deleveraging path blocked
MediumExpected ~40% decline by Q4 depends on margin expansion + cash generation. If utilization stalls or prices soften, debt service risk rises. Leverage ratio not disclosed; covenant risk unknown.
Competitive intensity in specialty starch (Ambuja, Sanstar)
MediumValue-added products are new to Regaal. Competitors adding capacity. Export competitiveness on new products vs. global pricing unproven.
Working capital cycle stretched (130 days, inventory 208 days)
MediumSeasonal Apr–Jul maize procurement inflates inventory. Cash realization delayed. If utilization ramp slows, inventory buildup worsens, straining deleveraging timeline.
How the street is positioned
Price and trend: ₹95.84 as of 2026-08-20, in a bullish trend above its 20-day (₹86.36), 50-day (₹82.49), and 200-day (₹77.07) moving averages. The stock is 7% below its all-time high and up 67% from its 52-week low. RSI 68.3 is neutral, not yet overbought. Volume is increasing, a positive signal for momentum.
Institutional flows: FII ownership fell to 0.31% (from 0.34% prior quarter), and DII to 2.58% (from 2.82%). Promoter holding steady at 71.32%. The institutional trim is a yellow flag—it suggests the street's enthusiasm for the story is cooling, or near-term execution risk is spooking hedge funds / foreign investors.
Bulk/block activity: May 8 bulk buy by GM (9.65L shares @ ₹94.16) and smaller IRAGE trades. No promoter/insider selling near the highs. Activity is muted, consistent with a story where execution is still being proven.
Valuation context: At ₹95.84, the stock is trading near all-time highs, pricing in the full upside of the value-added pivot and utilization ramp. A 7% drawdown from ATH is modest; it suggests the market believes in the thesis but has already priced in most of the gain. If Q2 utilization disappoints or new products underperform, the stock has limited upside and significant downside risk.
1 · Q2 crushing volumes (target: 100–110k tons)
This is the utilization ramp test. If Q2 comes in >105k, the ramp-up thesis is intact. If <95k, utilization risk escalates materially and the stock reprices downward.
2 · Modified starch online by end Q2 (Sep 2026)
This is the first specialty starch product ramp. Customer acceptance and pricing on modified starch (cationic, carboxymethyl, pre-gel, spray) will signal whether Regaal can command premium pricing on value-added derivatives vs. competitors.
3 · Peak debt decline H2 and Q4 cash position
Management expects ₹735 Cr peak debt to fall ~40% by Q4 as working capital normalizes (Rabi maize procurement ends, inventory days compress). If H2 debt doesn't decline or inventory stays elevated, deleveraging risk escalates.
4 · Maize price seasonality (Sep spike risk)
Maize prices typically spike Sep, soften Oct. At current ₹22.5–24/kg, Regaal is benign. But if Sep maize spikes to ₹26+/kg, starch prices follow (pass-through). This would create near-term perception risk even if margins are protected.
Regaal is a steady execution story, not a step-change. Q1 proves the margin expansion thesis is real—mix shift is working, value-added revenue is growing, and operating leverage is kicking in. But the company must prove the utilization ramp (Q2 is the test at 100–110k tons) and commercialize specialty starch (modified starch Sep, dextrose Q4) on time and with pricing power. At ₹95.84, the stock is priced for execution; miss, and it's vulnerable to a 20–30% drawdown.
For holders, the number to track is Q2 crushing volumes (target 100–110k tons). If it comes in >105k, utilization ramp is intact and the bull case is on track. If <95k, ramp risk escalates materially. For buyers, wait for Q2 confirmation before stepping in near all-time highs. This is a story that proves itself quarter by quarter, not a screaming bargain today.
Transition quarter soft on revenue, strong margins; ramp-up credible but unproven
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 numbers delivered as reported; guidance softened from 'doubling' to ~50% growth for FY27, not formally cut
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 revenue fell 18% YoY despite capacity doubling (transition quarter conceit is credible but still a miss). PAT grew 47% on margin expansion and reduced trading. Management's FY27 guidance (400k+ tons, 20–22% value-added) is realistic but a downgrade from prior 'potentially doubling' rhetoric. Long-term plan (FY28: 35% value-added, 50:50 capacity split) is solid, but execution risk remains high: utilization only 71%, new products ramping, ₹735 Cr peak debt, and commodity price exposure unquantified.
₹202.1 Cr
Revenue · −18% YoY₹13.3 Cr
Reported PAT · +47% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Value-added products grew 30.3% YoY to ₹80.53 Cr
METCall confirms ₹80.53 Cr value-added revenue, 30.3% YoY growth, 39.8% margin (1,477 bps expansion)
Revenue decline of 18% YoY due to deliberate reduction in trading activity
METDelivered ₹202.1 Cr vs. prior-year ~₹246 Cr; trading fell to 3.3% vs. 19.5% prior year
EBITDA rose 26.6% YoY to ₹30.98 Cr with 15.3% margin
METDelivered ₹30.98 Cr EBITDA, 15.3% margin (540 bps expansion) confirmed
Crushing volumes rose to 69,689 metric tons from 64,770 in Q1 FY26
OVERSTATEDQ1 increase of ~5,500 tons (8% growth), but well below prior year expansion expectations
We expect to crush ~400,000+ tons in FY27 vs. 265,000 in FY26
OVERSTATEDQuantified forward guidance; represents ~50% growth, not the prior 'potentially doubling' rhetoric
Earnings quality
What changed since the last call
Volume guidance downgraded
DowngradePrior: 'potentially doubling' (aspirational). Now: 400k+ tons for FY27 (~50% vs. FY26's 265k). Realistic for transition year but miss vs. prior rhetoric
Value-added target for FY27 eased
DowngradePrior guidance: 20–25%. Current Q1 delivery: 39.8% of value-added margin but only 80.5/202 = ~40% of revenue. FY27 target now 20–22% (lower bound of prior range)
Interest cost guidance reaffirmed
MaintainedFY27 net interest cost ₹39–40 Cr (vs. FY26 ~₹7.9 Cr Q1 quarterly run-rate); Bihar subvention caps effective borrowing cost
No new capex; stabilization focus
WithdrawnPrior: expansion phase (₹664 Cr project, ₹552 Cr spent by Jun 30). New: 'we want to consolidate and stabilize this...then start thinking' for next expansion
Export contribution doubled
UpgradeExports rose from 4.9% to 10.4% YoY; management targeting South, West, and new geographies for value-added products
The Q&A
Analysts pressed hard on EBITDA per ton (Diwakar, Prem Soni, Surya Narayan) and sustainable margins. Management held firm: refused per-ton EBITDA guidance citing commodity price dependency (maize/finished goods not controllable). On starch pricing trend, Q&A with Rohit Sinha revealed no specific % change ready (promised follow-up). Pushback on competition (Gujarat Ambuja, Sanstar specialty starch) met with export/market-opening answers. Overall: disciplined but firm, not evasive.
Capacity utilization path — Shivam Gupta, Trinetra Asset Managers
AnsweredPlant started Jun 1–2 (commissioned May 26). Utilization increasing, aiming for maximum within year. Q2 expected ~100–110k tons (vs. Q1's 69.7k)
Value-added product split — Shivam Gupta, Trinetra Asset Managers
AnsweredQ1 added 5,500 tons split between liquid glucose (~4,500 estimate) and maltodextrin (small). FY27 value-added target 20–22% of revenue (vs. 3% in FY26)
PAT growth drivers — Shivam Gupta, Trinetra Asset Managers
AnsweredMajorly operating leverage. Trading activity fell from 19% to 3% of turnover; manufacturing margins much higher. Raw material cost neutral year-on-year
Competitive pricing power — Shivam Gupta, Trinetra Asset Managers
PartialNever faced selling challenge in past. Exports up 5%→10%, opening South/West markets. Expanded liquid glucose capacity 180→825 TPD prior, sold all. Not a concern
Sustainable EBITDA per ton — Diwakar, Prudent Equity
DodgedCannot guide in transition phase. EBITDA per ton function of commodity prices + mix + leverage. Will improve with value-add but cannot quantify pre-commodity visibility
Net interest cost FY27 — Diwakar, Prudent Equity
AnsweredCFO: ₹39–40 Cr for FY27 (i.e., ~₹9.75–10 Cr/Q), flat vs. FY26 on subvention benefits. All capex debt qualifies for interest subvention
Future expansion plans — Diwakar, Prudent Equity
DodgedToo early to discuss next expansion. Stabilizing current one. No formal guidance on future capex or geography
Volume increase from new capacity — Rohit Sinha, Sunidhi Securities
AnsweredQ1 up 5,500 tons (8%), 64.7k→69.7k. Old plant volumes held; new 5,500 all new contribution. Q2 expect 100–110k tons if no issues
Starch pricing trend — Rohit Sinha, Sunidhi Securities
PartialConversion rate (maize-to-starch) better in FY27 vs. FY26. Specific % price change not calculated; will follow up via IR team
Export market opportunity — Omkar Kadam, individual investor
PartialExports 10% now (vs. 5% prior). Opening new geographies, attending trade fairs. No specific target given; volume-dependent
Co-product value-add potential — Omkar Kadam, individual investor
DodgedPossibility is feed plant, but that's a different line. Not explored yet on margin/value-add. No concrete plan
Inventory management — Madhur Rathi, Counter Cyclical Investments
Answered80% of FY27 inventory procured Rabi (Apr–Jul); 10–15% from other states (Maharashtra, MP, Karnataka). Exploring Kharif crop in Bihar (~6 lakh tons, new). Inventory seasonal; should normalize as utilization ramps
Cost advantage vs. peers — Madhur Rathi, Counter Cyclical Investments
AnsweredBihar/Karnataka maize best: 280–290 grams per 100 grains vs. 350–400 elsewhere. Direct farmer procurement (no logistics). Bihar low inherent consumption, so Regaal gets bulk at cheaper rates. Quality premium
EBITDA margin expectations — Madhur Rathi, Counter Cyclical Investments
PartialEBITDA margin will improve, but combination of commodity prices (uncontrollable), mix (ramping), and leverage (scaling). Inventory priced to be competitive with Kharif (Nov–Jan). Specific margin wait until year of experience
Maize price exposure — Harsh Saraswat, Srujan Alpha Capital
AnsweredAt doorstep getting ₹22.5–23/kg, good quality. Maize prices seasonally higher Sep, soften Oct. Holding substantial stock for year; if prices rise, starch prices rise, offsetting impact. Not a concern
Global maize pricing competitiveness — Harsh Saraswat, Srujan Alpha Capital
AnsweredIndian maize prices low vs. Ukraine/USA. Starch exports globally very competitive. Even at ₹24–25/kg, Indian exports competitive per industry association calc
Peak debt trajectory — Harsh Saraswat, Srujan Alpha Capital
AnsweredAlready peaking, will be in H1 balance sheet. Working capital highest H1 (seasonal maize purchase). H2 debt will decline ~40% (e.g., ₹100 Cr debt→₹40 Cr by Q4)
FY27 capex plans — Harsh Saraswat, Srujan Alpha Capital
AnsweredNo. Want to stabilize current expansion, get to 90–95% utilization, improve results, decrease debt first. Then think about next capex
Q1 production loss — Surya Narayan, Sunidhi Securities
AnsweredIntegration shutdowns: 9 days × ~800 TPD = ~7,200 tons lost. Liquid glucose at 70% capacity (ramp-up continuing). Maltodextrin 2–3 months to target. Q2 expected ~100–110k tons
Value-added product margin hierarchy — Surya Narayan, Sunidhi Securities
PartialDextrose light of day by Q4. Maltodextrin higher margin & value-add but lower volume (50 vs. 200 tons/day liquid glucose). Modified starch portfolio online by Sep, very high margin. Mixed basis, 100% value-add to 35–40%
FY28 value-added target — Surya Narayan, Sunidhi Securities
AnsweredCapacity designed 50:50 starch/value-add. From guidance perspective, take 35% confidence. Automatically 30–35% turnover. FY27 ~20% expected (this year will be difficult to gauge)
Margin multiple sensitivity to commodity prices — Surya Narayan, Sunidhi Securities
AnsweredStarch manufacturing: whole-number trade, not percentage-wise. If maize up, starch up; if down, down. EBITDA stays relatively constant if prices move together. Won't see % leverage on gross basis
Value-added go-to-market strategy — Navin, individual investor
AnsweredProducts made immediately, capacity online by Sep. 80–90% flowing to current channels (dealers, institutions, paper mills, food industry). New channels (batteries, oil drilling) ~20–30% upside. Big MNC customers acquired for liquid glucose (direct billing). Investments capitalized with main project
White-labelling status — Navin, individual investor
AnsweredCompletely on. Base increased, new customers added. India White brand live, existing customers increasing orders. Cross-selling and new customer additions both happening
Blended EBITDA margin FY27+ — Prem Soni, individual investor
DodgedMargins function of 3 variables: commodity prices (uncontrollable), value-add % (increasing), scale (improving). Cannot give firm guidance on % EBITDA margin. At same price levels, will do better due to leverage & value-add
Sales team breakup — Prem Soni, individual investor
DodgedDetailed data not ready; will be available from IR team on request
Guidance
FY27 crushing volumes ~400k+ tons (vs. 265k in FY26)
MediumRepresents ~50% growth; Q2 100–110k expected. 'Realistic for transition phase' tone; not the prior 'potentially doubling' rhetoric
FY27 value-added products 20–22% of revenue; FY28 guidance 30–35%
MediumQ1 actual 39.8% value-added margin but only ~40% of total revenue. FY27 20–22% is ramp phase; FY28 30–35% anchored on capacity 50:50 split
No per-ton EBITDA guidance; margin function of commodity prices (uncontrollable), mix (ramping), and scale (improving)
LowManagement disciplined on refusal; at same price levels, will improve vs. Q1 on value-add & leverage. Maize prices ₹22.5–24/kg; starch prices move in tandem
No FY27 capex. Focus on stabilization of ₹664 Cr project (₹552 Cr spent by Jun 30); next expansion post FY27
HighManagement explicitly deferring next capex decision until current expansion stabilizes and debt reduces. No geographic expansion planned near-term
Risks the call surfaced
Utilization ramp-up failure
HighQ1 utilization 71.4% post-commissioning (9-day integration loss ~7,200 tons). If Q2–Q3 ramp stalls, volume targets (400k+ tons FY27, 100–110k Q2) miss, and operating leverage disappears.
New product commercialization risk
HighLiquid glucose 70% capacity; maltodextrin 2–3 months to ramp. Dextrose Anhydrous/Monohydrate not live until Q4. Modified starch trials online by Sep. Customer acceptance and pricing power on new products unproven.
Commodity price exposure
HighMaize prices ₹22.5–24/kg (seasonal Sep spike). EBITDA per ton is 'whole-number trade'—if maize +₹1, starch +₹1 (offsetting), EBITDA flat. At ₹26–27/kg (last year peak), industry struggled. Current guidance unquantified because of commodity exposure.
Peak debt and deleveraging risk
MediumNet debt ₹735 Cr (peaked H1) from ₹664 Cr capex project. Deleveraging depends on utilization ramp and margin expansion. If ramp stalls or commodity prices soften, debt service/covenant risk rises.
Competitive intensity in specialty starch
MediumGujarat Ambuja and Sanstar adding specialty starch capacity (mentioned by analyst). Pricing power on new modified starch products unproven. Management claims no past challenge selling, but value-added is new category for Regaal.
Working capital cycle stretched
MediumCash conversion cycle 130 days, driven by high inventory (208 days) to support 1,650 TPD capacity. Seasonal Q1–Q2 maize procurement exacerbated this year. Tight working capital delays cash generation.
Management
Score 6/10. Disciplined and transparent on limitations (e.g., refused per-ton EBITDA guidance citing commodity price dependency). Answers on volumes/execution direct and quantified (400k+ tons FY27, 100–110k Q2, liquid glucose 70%, maltodextrin 2–3 months). Some evasion on specifics (starch pricing trend, detailed marketing team breakup promised for follow-up). Track record: 825→180 TPD liquid glucose capacity expanded and sold out prior (positive). Current quarter: 5,500 tons new volume added on 1,650 TPD (8% utilization gain from greenfield, reasonable for integration phase). Integration loss quantified (9 days, ~7,200 tons). On-track for ₹664 Cr capex project (₹552 Cr spent Jun 30). Guidance softened vs. prior 'doubling' to 400k+ tons (~50% growth), realistic for transition.
1 · Q2 FY27 (Sep 2026)
Utilization expected to improve as incremental 5,500 monthly volumes ramp; liquid glucose 70%→80%+ target
2 · Sep 2026
Modified starch trials complete (cationic, carboxymethyl, pre-gel, spray starch); online by end Q2
3 · Q3 FY27 (Dec 2026)
Peak debt expected to decline as H2 reduces working capital; Kharif maize procurement eases
Long-term plan (FY28: 35% value-added, 50:50 capacity split) is solid, but execution risk remains high: utilization only 71%, new products ramping, ₹735 Cr peak debt, and commodity price exposure unquantified.